Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2025)

InMed Pharmaceuticals' Return on Capital Employed history spans 4 years, with the latest figure at 0.73% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 29.0% year-over-year to 0.73%; the TTM value through Dec 2025 reached 0.73%, up 29.0%, while the annual FY2025 figure was 0.67%, 8.0% up from the prior year.
  • Return on Capital Employed reached 0.73% in Q4 2025 per INM's latest filing, down from 0.62% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.52% in Q1 2024 to a low of 1.73% in Q3 2022.
  • Average Return on Capital Employed over 4 years is 0.92%, with a median of 0.75% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: surged 105bps in 2023, then plummeted -64bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 1.19% in 2022, then surged by 49bps to 0.61% in 2023, then crashed by -68bps to 1.02% in 2024, then increased by 29bps to 0.73% in 2025.
  • Per Business Quant, the three most recent readings for INM's Return on Capital Employed are 0.73% (Q4 2025), 0.62% (Q3 2025), and 0.75% (Q2 2025).